Intravenous Diuretics in Nephrotic Syndrome

Intravenous Diuretics in Nephrotic Syndrome: When Oral Therapy Is Not Enough

1. Introduction

Nephrotic syndrome, which is common in systemic amyloidosis and other renal diseases, is defined by severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. Primary treatment usually consists of oral diuretics with concomitant sodium restriction, which treats mild to moderate fluid overload well.

But in patients with diffuse edema (anasarca) or nonresponse to high doses of oral diuretics, intravenous (IV) diuretics are required. These drugs exert prompt and effective fluid removal, alleviating symptoms and avoiding complications like pulmonary edema or cardiac stress.

This article discusses indications, mechanisms, dosing strategies, monitoring, supportive care, and outcomes of intravenous diuretics for nephrotic syndrome in detail.

2. Pathophysiology of Nephrotic Syndrome Edema

Edema in nephrotic syndrome occurs due to:

• Hypoalbuminemia: Plasma protein loss reduces oncotic pressure, allowing fluid to migrate into interstitial space
• Sodium retention: Increased renal sodium reabsorption leads to fluid overload
• Secondary hyperaldosteronism: The kidneys attempt to compensate for reduced circulating volume, exacerbating edema
  Diffuse edema or anasarca develops when these mechanisms are severe and result in generalized swelling, including periorbital, abdominal (ascites), and peripheral edema.

Case Example:

A 65-year-old man with AL amyloidosis had full-body edema, including severe ascites, that was not responsive to oral diuretics. IV diuretics caused prompt symptom relief in days.

3. Indications for Intravenous Diuretics

IV diuretics are considered in:

1. Diffuse edema / anasarca – generalized, severe fluid accumulation
2. Oral resistance to therapy – patients failing to respond to high-dose oral loop diuretics
3. Gastrointestinal dysfunction – inability of oral drugs to be absorbed due to gut edema or failure
4. Symptom relief rapidly required – pulmonary edema or acute dyspnea
   Clinical Tip:

Assess renal function and volume status prior to starting IV therapy to prevent hypovolemia or aggravation of kidney damage.

4. Mechanism of Action of Intravenous Diuretics

• Loop diuretics (e.g., furosemide, bumetanide, torsemide): Block sodium, potassium, and chloride reabsorption in the thick ascending loop of Henle, leading to potent diuresis.
• Thiazide diuretics (e.g., metolazone) used adjunctively: Interfere with sodium reabsorption in the distal tubule and increase loop diuretic potency.
• Combination therapy: In cases of diuretic resistance, synergistic combination of loop and thiazide diuretics is effective.

5. Dosing Strategies

5.1 Initial IV Loop Diuretics

• Furosemide: 20–40 mg IV, every 6–8 hours as needed depending on response
• Bumetanide: 0.5–1 mg IV equivalent dosing
• Dose may be increased in hypoalbuminemic patients due to decreased protein binding

5.2 Continuous Infusion

• Reserved for patients who do not respond to intermittent bolus dosing
• Offers constant diuresis, decreases peaks and troughs, and minimizes electrolyte changes
• Typical initial infusion: furosemide 10–20 mg/hour, titrated according to urine output

5.3 Combination Therapy

• For refractory edema, include thiazide (e.g., metolazone 2.5–5 mg orally) 30–60 minutes before IV loop
• Close observation needed because of potential for severe electrolyte loss

6. Monitoring During IV Diuretic Therapy

*

• Fluid balance: Monitor urine output, daily weight
• Vital signs: Heart rate, blood pressure
• Electrolytes: Potassium, sodium, magnesium, calcium
• Renal function: eGFR, creatinine
• Signs of overdiuresis: Prerenal azotemia, dizziness, hypotension
  Clinical Tip:
• Steer clear of aggressive diuresis in patients with marginally compromised kidney function
• Modify infusion rates or replace electrolytes as appropriate

7. Complications and How to Overcome Them

*

• Hypokalemia and hyponatremia: Lab check and replace electrolytes
• Hypovolemia / hypotension: Reduce dose or reduce infusion
• Ototoxicity (rare): Particularly with high-dose furosemide
• Diuretic resistance: Break through with combination therapy or albumin co-infusion in severe hypoalbuminemia
  Case Example:

A 58-year-old anasarca patient with AL amyloidosis developed hypokalemia following high-dose IV furosemide. Electrolytes were corrected, and treatment was continued safely.

8. Adjunctive Measures

• Restriction of sodium (<2 g/day)
• Fluid restriction in severe edema or hyponatremia
• Albumin infusion: Rarely used with IV diuretics in severe hypoalbuminemia to enhance diuretic response
• Nutritional support: Ensure proper protein intake while managing fluid overload

9. Case Studies and Real-World Applications

• Case 1: Refractory edema in a 62-year-old female was treated with IV combination of furosemide and metolazone, with 3 kg fluid loss in 24 hours.
• Case 2: Pulmonary edema due to nephrotic syndrome in a 65-year-old male was rapidly improved with continuous IV infusion of furosemide.
• Observation: Early IV treatment decreases hospitalization, enhances symptom relief, and avoids complications such as pulmonary edema.

10. Patient Education and Follow-Up

• Educate patients on daily weights and signs of fluid overload
• Reinforce dietary sodium restriction
• Address importance of follow-up labs for electrolytes and kidney function
• Encourage compliance with oral diuretics once IV therapy stabilizes fluid status

11. Future Perspectives

• Studies on novel diuretics and combination strategies to circumvent resistance
• Creation of personalized dosing protocols based on albumin levels and kidney function
• Combination with disease-specific treatments (such as for amyloidosis or other etiologies) to advance reduction of edema in the long term

12. Conclusion

Intravenous diuretics are crucial for patients with severe edema, anasarca, or intolerance to oral therapy in nephrotic syndrome. Accurate dosing, close monitoring, and supportive care like sodium restriction maximize results and reduce complications.

Early diagnosis and prompt initiation of IV therapy may improve quality of life dramatically, avoid complications, and stabilize patients while underlying disease is being treated.